Cardiovascular Medicine Book


PCSK9 Small Interfering RNA

Aka: PCSK9 Small Interfering RNA, Inclisiran, Leqvio
  1. See Also
    1. Hyperlipidemia Management
    2. PCSK9 Inhibitor (Praluent, Repatha)
  2. Mechanism
    1. PCSK9 Small Interfering RNA
    2. Prevents translation of PCSK9 Protein
    3. As with PCSK9 Inhibitors, up regulates hepatic LDL receptors
      1. Results in increased LDL clearance from blood
      2. Lowers LDL 50% in combination with high dose Statin
  3. Precautions
    1. Cost $6500/year in addition to clinic dosing administration cost
  4. Dosing: Inclisiran (Leqvio)
    1. Inclisiran SQ at 0, 3 and 6 months, then every 6 hours (in office)
  5. References
    1. (2022) Presc Lett 29(2): 7-8

You are currently viewing the original '\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree